Acute Coronary Syndrome
Acute Coronary Syndrome (ACS) is a condition characterized by a sudden reduction or blockage of blood flow in the coronary arteries, leading to heart muscle damage or dysfunction; it typically presents with centrally located chest pain, often radiating to the left shoulder or jaw and accompanied by nausea and sweating, though symptoms can vary, especially in women, older adults, and individuals with diabetes. Common manifestations of ACS include heart attacks (myocardial infarction) and chest pain (angina).
Health Outcomes
- Changed QT Interval Length
- Changed Secretory Phospholipase A2 Level
- Developed Polymorphic Ventricular Tachycardia
- Improved CVD-Related Symptom
- Improved Cardiac Muscle Contractile Performance
- Improved Cardiovascular Function
- Improved Combined Cardiopulmonary Outcomes
- Improved Event-Free Survival
- Improved Fractional Shortening
- Improved Hemodynamic Stability
- Improved Hospital Discharge
- Improved Left Ventricular Global Longitudinal Strain
- Improved Myocardial Strain Rate
- Improved Perceived Recovery
- Improved Post-Myocardial Infarction Outcome
- Improved Prognosis
- Improved Prognosis After Bacteremia Recovery
- Improved Survival at 24 Months
- Improved Tissue Oxygen Saturation Index
- Improved Treatment Effective Rate
- Improved Troponin T Level
- Increased Days Alive and Out of Hospital
- Increased Endothelial Progenitor Cell Count
- Increased Mortality
- Increased Treatment Success Rate
- Inhibited Platelet Aggregation
- Mitigated Cardiac Injury from Myocardial Infarction
- Modified LDL Phosphatidylcholine Composition
- No Change in Major Cardiovascular Event
- No Difference in Adverse Events
- No Long-Term Impact on Gut Microbiota
- Normal Safety Parameters
- Prolonged QT Interval
- Reduced Acute Kidney Injury
- Reduced Aortic Pressure
- Reduced Apolipoprotein A1 Level
- Reduced Apolipoprotein B-100 to Apolipoprotein A-1 Ratio
- Reduced Atherosclerotic Plaque Formation
- Reduced Bed Rest Occurrence
- Reduced Cardiac Arrest Risk
- Reduced Cardiac Arrhythmia
- Reduced Cardiac Biochemical Marker
- Reduced Cardiac Damage
- Reduced Cardiac Event
- Reduced Cardiac Function
- Reduced Cardiovascular Event
- Reduced Chest Pain
- Reduced Contrast-Induced Acute Kidney Injury
- Reduced Duration of Dobutamine Use
- Reduced HMG-CoA Reductase Inhibition
- Reduced Hospital Mortality Rate
- Reduced Hospital Readmission Risk
- Reduced Hospital Stay
- Reduced Hospitalization Day
- Reduced Hospitalization Duration
- Reduced Hospitalization Rate
- Reduced In-hospital Mortality
- Reduced Inotropic Support Requirement
- Reduced Intensive Care Unit Length of Stay
- Reduced Intensive Care Unit Mortality
- Reduced Intensive Care Unit Outcome
- Reduced LDL Aggregation
- Reduced Left Ventricular Ejection Fraction Decline
- Reduced Length of Hospitalization
- Reduced Length of Stay
- Reduced Life Threatening Complication
- Reduced Mortality
- Reduced Mortality Rate Before Discharge
- Reduced Mortality Rate under Stress
- Reduced Myeloperoxidase Levels
- Reduced Myocardial Infarct Size
- Reduced Myocardial Injury
- Reduced Myocardial Injury Cytokines
- Reduced Organ Dysfunction
- Reduced Organ Failure Severity
- Reduced Platelet Function Marker Level
- Reduced Platelet Hyperactivation
- Reduced Pulse Rate
- Reduced Serum Amyloid A Levels
- Reduced Short-term Mortality
- Reduced Short-term Recurrence
- Reduced Statin Discontinuation Rate
- Reduced Survival Rate
- Reduced TXB2 Level
- Reduced Thrombosis
- Reduced Thromboxane A2 Level
- Reduced Time to Crisis Resolution
- Reduced Unplanned Medical Re-presentations
- Reduced Unplanned Re-presentation
- Reduced Unstable Angina